B6-hFOLH1 (hPSMA) Mouse
제품명
B6-hFOLH1 (hPSMA) Mouse
제품 ID
C001779
품종 계통
C57BL/6NCya-Folh1tm1(hFOLH1)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “B6-hFOLH1 (hPSMA) Mouse (카탈로그 번호 C001779)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
PSM, FGCP, FOLH, GCP2, PSMA, mGCP, GCPII, NAALAD1
NCBI ID
염색체
Chr 11
MGI ID
Datasheet
품종 계통 설명
The FOLH1 gene, also known as prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII), encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. This protein functions as a glutamate carboxypeptidase, acting on various substrates including the nutrient folate (essential for its intestinal absorption) and the neuropeptide N-acetyl-l-aspartyl-l-glutamate (NAAG). In the brain, FOLH1 modulates excitatory neurotransmission by hydrolyzing NAAG, thereby releasing glutamate [1]. It is expressed in a wide range of tissues, including the prostate, central and peripheral nervous systems, kidney, small intestine, liver, and various tumor-associated vasculatures [2]. Aberrant expression of FOLH1 is notably associated with several diseases; it is significantly upregulated in prostate cancer cells and is a crucial diagnostic and prognostic indicator for this malignancy. Additionally, mutations in FOLH1 can lead to impaired intestinal absorption of dietary folates, resulting in low blood folate levels and hyperhomocysteinemia [3]. Its expression in the brain has also been implicated in pathological conditions related to glutamate excitotoxicity, and it is increasingly recognized as a therapeutic target in various solid tumors beyond prostate cancer, such as hepatocellular carcinoma, breast cancer, and Merkel cell carcinoma [2].
The B6-hFOLH1 mouse is a humanized model constructed by replacing aa.45 to partial intron 2 of the mouse Folh1 gene with the human FOLH1 cDNA of the extracellular domain (aa.44~750)-3’UTR of mouse Folh1-WPRE-BGH pA cassette. The murine cytoplasmic-transmembrane domain (aa.1~44) will be preserved. B6-hFOLH1 mice can be used for research into the pathogenesis of hyperhomocysteinemia and various solid tumors like prostate cancer, as well as for the screening, development, and safety evaluation of FOLH1-targeted drugs.
Reference
Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025 Jan;22(1):26-45.
Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368.
Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, Halsted CH. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet. 2000 Nov 22;9(19):2837-44.
변형 전략
The region from aa.45 to partial intron 2 of mouse Folh1 will be replaced with the human FOLH1 cDNA of the extracellular domain-3’UTR of mouse Folh1-WPRE-BGH pA cassette. The murine cytoplasmic-transmembrane domain will be preserved.
Figure 1. Gene editing strategy of B6-hFOLH1 Mice.
응용 분야
FOLH1-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of hyperhomocysteinemia;
Research on the pathological mechanisms and therapeutic approaches of various solid tumors like prostate cancer.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.